Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:05 AM ET 8-K
Financial Results Camden National Corp CAC

Camden National Financial Results

Camden National Corporation reported Q3 2026 net income of $22.8 million and diluted EPS of $1.34, representing an 8% increase in net income year-over-year. The results were driven by 5% deposit growth and a 15 basis point expansion of the net interest margin to 3.41%.

Term
Q3 2026

“Our third-quarter results demonstrate continued momentum across the franchise, with year-over-year earnings growth, meaningful deposit growth, and strong credit performance.”

Simon Griffiths, President and Chief Executive Officer

“With record earnings through the first nine months of the year and a stronger balance sheet, we are confident that we are well positioned to deliver sustained earnings growth and long-term shareholder value.”

Simon Griffiths, President and Chief Executive Officer
8:03 AM ET 8-K
Financial Results Ecolab Inc. ECL

Ecolab Financial Results

Ecolab reported third quarter 2026 results featuring 13% reported sales growth and a 5% increase in adjusted diluted EPS to $2.18. The company highlighted strong organic sales growth of 63% in its Global High-Tech segment and 17% in Life Sciences, driven by the performance of recent acquisitions Ovivo Electronics and CoolIT.

Term
Q3 2026

“Third quarter results marked an inflection point in Ecolab's performance. Exceptional execution drove accelerating sales growth, margin expansion and double-digit adjusted operating income growth. Volume growth accelerated to 2% despite ongoing disruptions in the Middle East. As expected, pricing strengthened to 5% as we leveraged total value delivered to mitigate higher commodity costs while improving customer performance. This disciplined execution allowed us to stabilize our organic gross margin.”

Christophe Beck, Ecolab’s chairman, president and chief executive officer
8:02 AM ET Form 4
Insider Buying Obook Holdings Inc. OWLS

Obook Holdings CEO Chun Kai Wang Buys $22.3K of Stock

Chun Kai Wang, CEO, bought 11,105 shares of Obook Holdings Inc. at $2.01 a share, worth $22.3K in total on Oct 26, 2026. Shares held after the trade: 3,148,105 (+0.4%).

Value
$22.3K
Shares
11,105
Price
$2.01
Role
CEO
Holding change
+0.4%
Trade date
Oct 26, 2026
8:01 AM ET 8-K
Financial Results Cts Corp CTS

Cts Financial Results

CTS Corporation reported third-quarter 2026 sales of $149.6 million, a 5% increase year-over-year driven by strength in diversified end-markets. The company achieved record margins and raised its full-year 2026 guidance for both sales and adjusted EPS, citing disciplined execution and the strategic acquisition of Millar.

Term
Q3 2026

“CTS delivered another strong quarter, with sales increasing 5% year over year, driven by continued strength across our increasingly diversified portfolio. Diversified end-market sales grew 7% and now represent 60% of total sales, while Transportation sales also posted modest growth.”

Pratik Trivedi, CEO of CTS Corporation

“Our disciplined execution is delivering profitable growth, record margins and strong cash generation. The acquisition of Millar further advances our diversification strategy, especially in the medical end market, and enhances our opportunity to create sustainable long-term value.”

Pratik Trivedi, CEO of CTS Corporation
8:01 AM ET 8-K
Leadership Change Entera Bio Ltd. ENTX

Entera Bio Leadership Change

Entera Bio Ltd. appointed Dr. Juan Camilo Arjona Ferreira, currently the CMO of Organon & Co., as a Class II director effective December 1, 2026. Simultaneously, Haya Taitel notified the board of her resignation as a director, also effective December 1, 2026. Dr. Arjona Ferreira will participate in the company's standard non-employee director compensation program.

8:01 AM ET 8-K
Financial Results Smithfield Foods Inc SFD

Smithfield Foods Financial Results

Smithfield Foods reported third quarter 2026 sales of $3.4 billion, an 8.3% decrease year-over-year, driven by pressure in upstream pork commodity markets. Despite the decline, the Packaged Meats segment delivered higher operating profit and the company completed its acquisition of Nathan’s Famous to bolster its brand portfolio.

Term
Q3 2026

“We reported third quarter adjusted operating profit within the range we provided in September, led by strong results in our cornerstone Packaged Meats segment, with our upstream segments challenged by lower pork commodity markets.”

Shane Smith, President and CEO

“Packaged Meats remains on track to deliver its fifth consecutive year above $1 billion in operating profit in fiscal 2026. The completion of the Nathan’s Famous acquisition further strengthens our brand portfolio and expands our opportunities for profitable growth.”

Shane Smith, President and CEO
8:01 AM ET 8-K
Financial Results Central Bancompany, Inc. CBC

Central Bancompany Financial Results

Central Bancompany reported Q3 2026 net income of $116.2 million, or $0.48 per diluted share, driven by net interest margin expansion to 4.48%. The company saw average total deposits grow 4.4% year-over-year to $15.4 billion, while maintaining strong asset quality with nonperforming assets at just 33 basis points of total assets.

Term
3 years

“We delivered another strong quarter, supported by continued balance sheet growth, disciplined expense management, and solid credit quality. Adjusted net income increased $13.7 million from a year ago and $2.8 million from the prior quarter.”

John “JR” Ross, President and Chief Executive Officer

“Underlying business fundamentals remained healthy across our franchise. Average total deposits increased more than 4% from the prior-year quarter, including 6% growth in noninterest-bearing deposits, while average loans grew at an annualized rate of more than 3% from the prior quarter despite our continued focus on reducing certain consumer loan balances.”

John “JR” Ross, President and Chief Executive Officer
8:00 AM ET 8-K
Financial Results Skyline Bankshares, Inc. SLBK

Skyline Bankshares Financial Results

Skyline Bankshares reported record third-quarter net income of $5.1 million, or $0.90 per share, driven by organic loan growth and an expanded net interest margin of 4.61%. Total assets grew to $1.35 billion, supported by a 6.92% increase in net loans since the end of 2025. The company also expanded its footprint with the opening of a new branch in Dobson, North Carolina.

Term
Q3 2026

“We are pleased to report another quarter of record earnings for Skyline while continuing to invest in future growth, including the September opening of our newest branch in Dobson, North Carolina.”

Blake Edwards, President and CEO

“We believe we remain well positioned for continued growth and success in the future and look forward to the opportunities ahead for the Skyline family.”

Blake Edwards, President and CEO
7:51 AM ET 10-Q
Financial Results Wave Life Sciences, Inc. WVE

Wave Life Sciences Q3 2026 Results: Net Loss of $61.9M, Loss Widens

Wave Life Sciences reported total assets of $507.9 million as of September 30, 2026, a decrease from $638.5 million at year-end 2025, primarily driven by a reduction in cash and cash equivalents. The company transitioned a significant portion of its liquidity into marketable securities and reported 197,228,968 shares of common stock outstanding as of October 21, 2026.

Key figure
Net loss $61.9M
7:50 AM ET 8-K
Stock Buyback Terrestrial Energy Inc. IMSR

Terrestrial Energy Announces $25M Stock Buyback

Terrestrial Energy's Board of Directors has authorized a share repurchase program to buy back up to $25 million of its common stock. The program will be funded from existing cash on hand and is scheduled to expire on October 22, 2027. Management will determine the timing and volume of repurchases based on market conditions and capital requirements.

Value
$25M
Term
through Oct 2027
7:48 AM ET 8-K
Financial Results Commvault Systems Inc CVLT

Commvault Systems Financial Results

Commvault Systems reported Q2 fiscal 2027 results with subscription revenue growing 21% year-over-year to $269 million and subscription ARR reaching $1.1 billion. The company raised its full-year fiscal 2027 guidance for subscription revenue and ARR, citing strong momentum in enterprise cyber resilience and AI-driven demand.

Term
Q2 2027

“With AI accelerating both innovation and risk in the enterprise, resilience continues to be a business imperative. Enterprises globally are increasingly turning to Commvault to stay resilient as they navigate more data, more identities, and greater complexity. We believe our strong Q2 results reflect that momentum, driving durable growth and shareholder value.”

Sanjay Mirchandani, President and CEO
7:47 AM ET 8-K
Financial Results Norwood Financial Corp NWFL

Norwood Financial Financial Results

Norwood Financial Corp reported record Q3 2026 net income of $11.8 million and record net interest income of $28.0 million. Results were driven by disciplined execution and contributions from the Presence Bank acquisition, alongside a net interest margin expansion to 4.01%.

Term
Q3 2026

“The entire Wayne Bank team continued to perform well in the third quarter, delivering record net income and net interest income for the second consecutive quarter. In addition to strong income growth, we navigated the bankruptcy related to a borrower relationship, resolving the issue with favorable outcome.”

Jim Donnelly, President and Chief Executive Officer
7:41 AM ET 8-K
Financial Results Zura Bio Ltd ZURA

Zura Bio Financial Results

Zura Bio reported third quarter 2026 financial results, highlighting a cash position of $187.7 million which is expected to fund operations through 2028. The company remains on track for topline Phase 2 data readouts for tibulizumab in hidradenitis suppurativa (Q4 2026) and systemic sclerosis (H1 2027).

“Our team continues to execute efficiently on our development plan for tibulizumab, and we are excited as we enter this data-rich period for the company. We are on track to report topline results from our TibuSHIELD study in HS later this quarter, followed by topline results from our TibuSURE study in SSc in the first half of 2027.”

Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer

“We continue to believe deeply in tibulizumab’s potential to address complex immune biology and unmet needs across indications, including in PMR, where we will be starting the NEXUS-PMR study by end of year. With cash runway sufficient to deliver results from all three studies, Zura is in a great position to deliver on tibulizumab’s unique potential.”

Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer
7:39 AM ET 10-Q
Financial Results Zura Bio Ltd ZURA

Zura Bio Q3 2026 Results: Net Loss of $25.8M, Loss Widens

Zura Bio Limited reported a net loss of $76.4 million for the nine months ended September 30, 2026, driven by increased research and development expenses. The company strengthened its balance sheet during the period, ending with $187.7 million in cash and cash equivalents compared to $109.4 million at the end of 2025.

Key figure
Net loss $25.8M
7:37 AM ET 10-Q
Financial Results Nautilus Biotechnology, Inc. NAUT

Nautilus Biotechnology Q3 2026 Results: Net Loss of $15.6M, Loss Widens

Nautilus Biotechnology reported total revenue of $424,000 for the nine months ended September 30, 2026, primarily from grant and service revenue, compared to zero revenue in the prior year. The company's total assets decreased from $191.1 million at the end of 2025 to $148.9 million as of September 30, 2026, driven by an accumulated deficit of $376.8 million.

Key figure
Net loss $15.6M
7:37 AM ET 8-K
Financial Results Wave Life Sciences, Inc. WVE

Wave Life Sciences Financial Results

Wave Life Sciences reported Q3 2026 financial results, highlighting a cash position of $431 million and an expected runway into Q3 2028. The company is advancing its RNA editing and siRNA clinical programs, including planning for a registrational trial of WVE-006 in AATD and ongoing Phase 2a dosing for WVE-007 in obesity.

Term
Q3 2026

“Following positive FDA feedback, planning is underway for our potentially registrational trial of WVE-006 for AATD, which we believe offers an efficient path to potential full and accelerated approval, without the need for a separate confirmatory trial.”

Paul Bolno, MD, MBA, President and Chief Executive Officer

“Importantly, our PRISM platform and chemistry continue to demonstrate unique value both within our own pipeline and beyond. The advancement of a development candidate by GSK reflects the recognition of Wave’s differentiated technology, including our best-in-class siRNA with SpiNA design, with three additional collaboration programs still advancing.”

Paul Bolno, MD, MBA, President and Chief Executive Officer
7:34 AM ET 8-K
Leadership Change Faeth Therapeutics, Inc. FTH

Faeth Therapeutics Leadership Change

Faeth Therapeutics increased its board size from six to seven and appointed Adam Schayowitz, Ph.D., as a Class III director. Dr. Schayowitz, currently EVP and Head of R&D at Zymeworks, brings extensive oncology drug development experience from previous roles at Pfizer and Tesaro. He will receive a standard non-employee director compensation package, including an initial option to purchase 25,000 shares of common stock.

7:33 AM ET 8-K
Financial Results Kiniksa Pharmaceuticals International, plc KNSA

Kiniksa Pharmaceuticals International Financial Results

Kiniksa Pharmaceuticals reported Q3 2026 financial results, highlighted by ARCALYST net product revenue of $286.0 million, a 58% year-over-year increase. The company raised its full-year 2026 ARCALYST net product revenue guidance to a range of $1.045 billion to $1.050 billion.

“Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis. In the third quarter, strong commercial execution led to gains in patient and physician adoption, resulting in revenue of $286.0 million and positioning ARCALYST to achieve blockbuster status this year”

Sanj K. Patel, Chairman & Chief Executive Officer of Kiniksa
7:32 AM ET Form 4
Insider Buying Agora, Inc. API

Agora CEO Bin Zhao Buys $78.1K of Stock

Bin Zhao, CEO, bought 17,598 shares of Agora, Inc. at $4.42 to $4.47 a share (average $4.44) in 2 transactions, worth $78.1K in total between Oct 23, 2026 and Oct 26, 2026. Shares held after the trade: 2,222,333 (+0.3%).

Value
$78.1K
Shares
17,598
Average price
$4.44
Role
CEO
Holding change
+0.3%
Trade date
Oct 23, 2026 to Oct 26, 2026
7:31 AM ET 8-K
Other 8-K Filing Weatherford International plc WFRD

Weatherford International Other 8-K Filing

Weatherford International plc received approval from the High Court of Ireland to change its legal domicile from Ireland to Delaware, effective November 13, 2026. The redomestication will result in a new Delaware parent company, Weatherford International Corp, and is expected to trigger a non-cash tax benefit between $250 million and $300 million in Q4 2026.

7:31 AM ET 8-K
Financial Results Boeing Co BA

Boeing Financial Results

Boeing reported third quarter 2026 revenue of $24.2 billion and a net loss of $116 million, reflecting higher defense and services volume. The company achieved a record backlog of $745 billion and noted key milestones including FAA certification for the 737-7 and 737-10 aircraft.

Term
Q3 2026

“Recent milestones, including certification of the 737-7 and 737-10 and selection to design and build the Navy’s sixth-generation fighter aircraft, are important steps as we continue building on our progress. But we are not done. We remain focused on safety and quality as we redouble our efforts on Lean and disciplined execution to deliver on our commitments and build the durable performance our stakeholders expect.”

Kelly Ortberg, Boeing president and chief executive officer
7:30 AM ET 8-K
Financial Results Watsco Inc WSO

Watsco Financial Results

Watsco reported record third quarter sales of $2.22 billion, a 7% increase year-over-year, driven by stabilization in residential demand and recent acquisitions. The company recently completed the acquisitions of Jackson Supply Company and The Granite Group, which are expected to increase annual revenue by approximately 10%.

7:18 AM ET 8-K
Financial Results Celestica Inc CLS

Celestica Financial Results

Celestica Inc. reported its financial results for the third quarter ended September 30, 2026, alongside an Investor and Analyst Day presentation. The company disclosed GAAP earnings from operations of $460.0 million for Q3 2026 and a year-to-date GAAP ROIC of 55.9%.

Term
Q3 2026
7:18 AM ET 8-K
Financial Results HCA Healthcare, Inc. HCA

HCA Healthcare Financial Results

HCA Healthcare reported third quarter 2026 revenues of $19.85 billion, a 3.6% increase year-over-year, despite an estimated $400 million headwind from an unfavorable payer mix shift. The company also declared a quarterly cash dividend of $0.78 per share and indicated that full-year results are expected to be in the upper half of its previously issued guidance range.

Term
Q3 2026

“I have often mentioned that HCA has strong staying power because of our scale, the important role we play in providing critical services to communities, and our disciplined culture. Despite the challenges brought about by federal policy changes this year, our colleagues have continued to provide high-quality care to patients, and we believe HCA Healthcare is positioned to end the year positively.”

Sam Hazen, Chief Executive Officer of HCA Healthcare
7:16 AM ET 8-K
Financial Results S&P Global Inc. SPGI

S&P Global Financial Results

S&P Global reported Q3 2026 revenue of $3.68 billion, a 7% year-over-year increase, and initiated a strategic review for its Capital IQ and associated data businesses. The company also completed the spin-off of its Mobility division into an independent public company, Mobility Global, on July 1, 2026.

“S&P Global delivered a very strong quarter. Increasing demand for our benchmarks and unique intellectual property demonstrates our leadership in credit, equity, and commodities markets. Our focus on new high-growth adjacencies and our innovation are resonating deeply with customers around the world. The businesses that are part of the strategic review are strong and have significant opportunities ahead of them as technology changes how customers access, analyze, and use information. This reflects our long-standing commitment to be good stewards of our portfolio, while prioritizing our investments where we’re strongest.”

Martina Cheung, President and CEO
7:09 AM ET 8-K
Financial Results Iqvia Holdings Inc. IQV

Iqvia Holdings Financial Results

IQVIA reported third-quarter 2026 revenue of $4.43 billion, up 8.0% year-over-year, driven by strong growth in R&D Solutions and Commercial Solutions. The company achieved record clinical bookings of $3.2 billion and raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted Diluted EPS.

“IQVIA delivered another record quarter, with revenue, Adjusted EBITDA and Adjusted Diluted EPS all exceeding the high end of our expectations. Multiple demand indicators continue to validate the strengthening market environment. EBP funding, RFP flow, clinical trial starts, FDA approvals, outsourcing trends, and pipeline growth across clinical and commercial are all favorable.”

Ari Bousbib, chairman and CEO of IQVIA
7:06 AM ET 8-K
Financial Results Sherwin Williams Co SHW

Sherwin Williams Financial Results

Sherwin-Williams reported third quarter 2026 consolidated net sales growth of 7.9% to $6.86 billion, driven by gains across all reportable segments and selling price increases. While net income decreased slightly to $821 million, adjusted diluted EPS rose to $3.63, and the company narrowed its full-year adjusted earnings guidance.

Term
3 months

“Sherwin-Williams third quarter performance demonstrated the resilience of our Company and the strength of our strategy in a challenging demand environment. Despite muted underlying market volumes, we continued to win new customers, increase share-of-wallet and deliver sales growth across all three reportable segments, at or above our guidance, supported by the differentiated value and productivity our solutions deliver to customers.”

Heidi G. Petz, Chair, President and Chief Executive Officer

“We returned $749.0 million to shareholders in the quarter through dividends and share repurchases. Our team remains focused on serving our customers and controlling what we can control to continue top and bottom-line growth.”

Heidi G. Petz, Chair, President and Chief Executive Officer
7:06 AM ET 8-K
M&A Deal Guidewire Software, Inc. GWRE

Guidewire Software Signs $1.7B M&A Deal with Hyperexponential Ltd

Guidewire Software has entered into a definitive agreement to acquire Hyperexponential Ltd, a London-based provider of AI-native underwriting and pricing software, for a base purchase price of $1.7 billion in cash. The deal includes up to $400 million in additional contingent consideration based on recurring revenue targets and is expected to close in the second quarter of fiscal year 2027. To fund the acquisition, Guidewire secured a $1.0 billion senior secured incremental term loan commitment from Bank of America and Citibank.

Value
$1.7B
Counterparty
Hyperexponential Ltd

“Insurance is a distinctly complex industry, where the quality of risk decisions has an immense impact on business outcomes. Guidewire and hyperexponential are uniquely positioned to deliver industry-specific AI solutions that will transform commercial underwriting. Together we will bring greater and more scalable intelligence to the insurance decisions that will help underwrite the risks of tomorrow.”

Mike Rosenbaum, chief executive officer, Guidewire

“Guidewire is the most trusted name in P&C insurance technology, with deep expertise in managing and safeguarding the policy and risk information insurers rely on throughout the insurance lifecycle. Together, we’ll bring insight from submission to bind and from the individual risk to the entire portfolio. With hx and Guidewire, insurers will be able to respond to submissions faster and, more importantly, improve loss ratios and allocate capital more effectively.”

Amrit Santhirasenan, CEO and co-founder, hyperexponential
7:05 AM ET 8-K
Financial Results Galaxy Digital Inc. GLXY

Galaxy Digital Financial Results

Galaxy Digital reported Q3 2026 net income of $323 million, a significant recovery from a net loss in the prior quarter, driven by digital asset franchise strength and investment portfolio appreciation. The company also announced a $200 million increase to its share repurchase authorization and highlighted a $3.5 billion senior secured notes offering to fund its Helios data center expansion.

Term
Q3 2026

“Galaxy delivered a strong third quarter, reflecting the strength of our established Digital Assets franchise, significant appreciation across our investments portfolio, and the growing contribution from our Data Centers business. Our strategy is centered on two significant opportunities in the global economy: the modernization of financial markets through digital assets and the expansion of AI infrastructure. The progress we're making across both businesses is strengthening and diversifying our earnings profile, while positioning Galaxy to capitalize on substantial growth opportunities. We remain focused on disciplined execution and creating long-term value for our shareholders.”

Mike Novogratz, Founder and Chief Executive Officer
7:05 AM ET 8-K
Financial Results Repligen Corp RGEN

Repligen Financial Results

Repligen Corporation reported record third-quarter 2026 revenue of $209.3 million, representing 11% reported and 12.5% organic growth. The company also announced the completion of its BioLife Solutions acquisition in October and raised its full-year 2026 revenue guidance to a range of $844-$852 million.

“We delivered a record third quarter, with $209 million in revenue and 12.5% organic growth, driven by continued strength across our diversified portfolio. End-market demand continues to improve, with healthy trends in consumables and services complemented by a growing capital equipment order book.”

Olivier Loeillot, President and Chief Executive Officer

“The completion of the BioLife acquisition in October marks a significant milestone for Repligen, and integration is progressing well. Early customer feedback has been very encouraging, and we have already taken actions to realize a sizable portion of our expected operating expense synergies. Our strong year-to-date performance, continued order momentum and the addition of BioLife give us confidence to raise our full-year guidance again.”

Olivier Loeillot, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.